Europe is quietly losing one of its most strategic industries.
This analysis examines the European pharmaceutical industry decline and its implications for investors. For nearly a century, Europe was considered the “world’s pharmacy,” thanks to its world-class research institutions and stable regulatory environment.
However, by 2026, that leadership is fading. Europe now faces a dual threat: an aggressive, protectionist “America First” trade policy under President Donald Trump and a rapidly expanding, state-backed biotech boom in China.
The Erosion of European R&D Leadership
The shift in global medical research investment has been dramatic and is central to the European pharmaceutical industry decline.
According to ING, the global R&D landscape has been completely reshaped over the past three decades:
- The 1990 Benchmark: Europe accounted for nearly 50% of global pharma R&D, while the U.S. held roughly 33%
- The Modern Reality: The U.S. now dominates with 55%, while Europe has fallen to just 26%
This is more than a loss of prestige. It represents a structural outflow of high-paying jobs, scientific talent, and future tax revenues from Europe.
The U.S. Factor: Pricing Pressure and Trade Barriers
The pharmaceutical sector is increasingly shaped by what can be described as the “Trump Squeeze,” a set of policies forcing companies to prioritize between the U.S. and European markets.
Most-Favored-Nation (MFN) Pricing
The MFN policy ties U.S. drug prices to the lowest prices in other developed countries. As a result, Europe’s traditionally lower pricing model has become a liability.
If a pharmaceutical company accepts a lower price in markets like Germany or France, it risks triggering price cuts in the U.S. – the most profitable market globally. This dynamic directly accelerates the European pharmaceutical industry decline.
Tariffs and National Security Strategy
The U.S. increasingly views biotech supply chains as a national security issue. With tariffs on branded drugs reaching up to 100%, companies are incentivized to relocate manufacturing and R&D operations to the United States.
China’s Leap into Biotech Innovation
At the same time, China has rapidly transformed from a producer of generic chemicals into a leader in early-stage biotech innovation.
The Innovation Engine
Ten years ago, Chinese-developed molecules represented just 4% of the global drug pipeline. Today, they account for nearly one-third, marking a major shift in global innovation.
Strategic Partnerships
Global pharmaceutical companies are no longer just selling into China – they are actively sourcing innovation from Chinese labs. This has led to multi-billion dollar licensing deals and deeper cross-border collaboration.
According to PitchBook, China’s competitive advantage in biopharma is likely to persist due to targeted funding and differentiated scientific approaches, even amid geopolitical tensions.
Internal Challenges: Fragmentation and Regulation
Not all of Europe’s challenges are external. Structural inefficiencies within the region are also contributing to the European pharmaceutical industry decline.
The European market remains fragmented, with 27 different regulatory and reimbursement systems, creating significant barriers for startups and scaling companies.
Key Structural Differences
| Feature | Europe | United States |
|---|---|---|
| Venture Capital | 5x–10x less than the U.S. | Strong capital access |
| GDP Spending on Pharma | ~1% | ~2% |
| Regulatory Market | Fragmented (27 countries) | Unified (FDA) |
Nathalie Moll, Director General of the EFPIA, highlights a critical point: without the pharmaceutical sector, Europe would face an €88 billion trade deficit. Despite this, taxation and regulatory pressures continue to push innovation elsewhere.
The Patient Impact: Delayed Access to Innovation
One of the most significant consequences of the European pharmaceutical industry decline is reduced access to new treatments.
Due to U.S. pricing dynamics, companies must choose between maximizing value and expanding volume.
“For drugs where value is the priority, we will see postponements in launches in Europe,”
– Diederik Stadig, ING healthcare analyst
If launching in Europe threatens U.S. pricing power, companies may delay entry. As a result, innovative therapies available in cities like Boston or San Francisco often take years to reach patients in Berlin or Rome – if they arrive at all.
Is There a Path to Recovery?
Despite these challenges, there are emerging signs of recovery within Europe’s biotech ecosystem.
Policy Reforms
The EU’s proposed Biotech Act and Critical Medicines Act aim to reduce regulatory barriers and accelerate clinical trial approvals.
Regional Success Stories
Spain has emerged as a growing hub for clinical research through targeted government support, demonstrating that localized policy solutions can be effective.
Talent Dynamics
Potential budget cuts to the U.S. National Institutes of Health (NIH), combined with stricter immigration policies, may create an opportunity for Europe to attract global biotech talent, particularly in fields such as mRNA research.
Conclusion: Europe’s Strategic Crossroads
Europe has correctly identified the core issues behind its decline. Regulatory processes are improving, and biotech is becoming a policy priority.
However, without addressing deeper structural challenges – particularly pricing models and market fragmentation – the European pharmaceutical industry decline will continue.
The strategic question remains clear:
Will Europe reclaim its role as a global leader in pharmaceutical innovation, or will it become primarily a consumer of breakthroughs developed in the United States and China?